Can You Imagine This?
Dental Economics, December 9, 2019 – In 1971, John Lennon famously asked us to imagine a different world. His words still resonate today, and we can apply them to our own dental world.
Can you imagine people living without secondary caries? Can you imagine if we could treat white spots noninvasively? We don’t have to imagine anymore. Let me introduce to you incredible upcoming technologies from Nobio and GreenMark Bio.
GreenMark Secures Phase II SBIR Funding for Identification of Early Stage Dental Caries
East Lansing and Ann Arbor, MI – October 2, 2019 – GreenMark Biomedical Inc. today announced it has been awarded a $1.5m Phase II Small Business Innovation Research (SBIR) grant to further develop its patented nanoparticle-based dental technology for detection of early stage dental caries. The 2-year project involves collaboration with dental and biomaterials experts at the University of Michigan, Creighton University, Tufts University and University of Colorado, and is being funded by the National Institute of Dental and Craniofacial Research (NIDCR) of the National Institutes of Health (NIH).
After the Elevator Pitch
Fall 2019 – GreenMark Biomedical Inc. is a Michigan-based, minimally invasive healthcare company that was founded in 2016 by Dr. Steven Bloembergen with a mission to “enable dentists to preserve teeth through early diagnosis and treatment”. Dr. Bloembergen is a co-founder of EcoSynthetix Inc., a global bio-based nanoparticle manufacturer. In partnership with collaborators at the University of Michigan, GreenMark has expanded upon this proprietary technology by applying it to medicine and dentistry.
Bringing Early-Stage Carious Lesions to Light
September 30, 2019 – Using nanotechnology, GreenMark Biomedical is developing a non-invasive approach to diagnosing and treating active, incipient carious lesions.
The idea of nanodentistry may still seem a little like pure science fiction or a distant vision. In fact, products based on “small scale” targeted technology for diagnosing, treating and preventing caries may well be in your practice in the near future.
GreenMark Secures Additional Funding for Cavity Identification and Treatment
East Lansing and Ann Arbor, MI – March 19, 2019 – GreenMark Biomedical Inc. today announced it secured $670K equity funding completing a $1.2M Series Seed Preferred Stock round to further develop and commercialize its patented nanoparticle-based dental technology. The University of Michigan’s MINTS program, Invest Michigan and Red Cedar Ventures investments follow earlier funding from Blue Water Angels, Western Michigan University’s BRCC and Invest Detroit Ventures.
GreenMark Wins $100,000 in Funding at Accelerate Michigan: Reasons to be Thankful at Thanksgiving!
Detroit, MI – Nov. 21, 2018 – GreenMark Biomedical Inc. today announced it was awarded the $100,000 Second Prize at the 2018 Accelerate Michigan Innovation Competition (AMIC), which includes an investment from Invest Michigan and ID Ventures as well as a $25,000 grant. AMIC supports Michigan’s entrepreneurial ecosystem by inviting entrepreneurs to showcase their companies to Angel and Venture Capital investors, while building connections with fellow entrepreneurs and business acceleration resources.
GreenMark Secures Funding for Cavity Identification and Treatment Technology
Ann Arbor, MI – October 3, 2018 – GreenMark Biomedical Inc. today announced it secured funding for its patented dental technology that identifies ‘pre-cavities’ which can be treated non-invasively before becoming cavities. This will have major implications for treatment of tooth decay prior to the need for surgical treatment, resulting in improved oral health outcomes for patients.
GreenMark Biomedical Raises Seed Investment
Ann Arbor, MI – June 29, 2018 – GreenMark Biomedical Inc. today announced that it closed on $500K in equity investment. The round is led by BlueWater Angel Investment Network (BWA) of Saginaw, MI and funds flowed in May and June as part of a Rolling Close. Biosciences Research & Commercialization Center (BRCC), an early stage Life Science Investor out of Kalamazoo, MI also participated.
GreenMark to Present at the 37th Annual Michigan Growth Capital Symposium and Coulter Investment Forum May 15-16
Ann Arbor, MI – May 14, 2018 – GreenMark Biomedical Inc. today announced that it has been selected to present at the 37th annual Michigan Growth Capital Symposium (MGCS). GreenMark, a Delaware corporation with facilities in Michigan will be presenting to investors in attendance, including more than 100 top venture capital firms.
GreenMark Biomedical and University of Michigan Receive Phase I SBIR Funding for Diagnostic to Enable Minimally Invasive Dentistry
April 4, 2018 – GreenMark Biomedical Inc. today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant in the amount of US $228,883 from the National Institutes of Health (NIH). The grant will fund a collaborative project between GreenMark and the University of Michigan (U-M).
GreenMark Announced as Semifinalist for the 8th Annual Accelerate Michigan Innovation Competition
October 3, 2017 – The stage is set for the 8th Annual Accelerate Michigan Innovation Competition, the state’s largest convening of high-growth, high-tech companies and venture investors. Today, 36 innovative startups from a variety of high-growth sectors including advanced materials, manufacturing, alternative energy, business services, consumer products, information technology, life sciences/healthcare, media, mobility and more, learned they are this year’s semifinalists.
GreenMark Publication Highlighted in Advanced Science News
Our peer-reviewed publication, entitled “Nanoparticle-based targeting and detection of microcavities” published in Advanced Healthcare Materials is being highlighted in Advanced Science News.
GreenMark Selected to Participate in VentureWell ASPIRE Program
June 5, 2017 – GreenMark has been selected to partner with VentureWell through the ASPIRE Healthcare program. ASPIRE is an intense experiential workshop that prepares startups for the investments and partnerships necessary to launch their ventures. The program will be held at Detroit’s Techtown, June 26-June 30, 2017. Participants will engage with fellow healthcare startups and work with mentors who are experts in early-stage financing from around the country.
GreenMark to Present at the 36th Annual Michigan Growth Capital Symposium and Coulter Investment Forum May 16-17
Ann Arbor, MI – May 9, 2017 – GreenMark Biomedical Inc. today announced that it has been selected to present at the 36th annual Michigan Growth Capital Symposium (MGCS) and the jointly hosted Coulter Investment Forum. GreenMark, a Delaware corporation with facilities in Michigan will be presenting to investors in attendance, including more than 100 top venture capital firms. The company aims to deliver health benefits to society through biobased targeting technologies.
Biomedical Commercialization Course Awards Winning Team
Ann Arbor, MI – Nov 17, 2016 – On Friday, November 4, Fast Forward Medical Innovation ended the fifth cohort of the Early Tech Development (ETD) Course with a competition in which teams pitched their projects to the class and a panel of judges. Thirteen project teams graduated from the 4-week program that is designed to provide the knowledge and tools needed to navigate the initial process of innovation and commercialization. Congratulations to the winning project teams!
Overall Winner & Therapeutics/Diagnostic Track Winner:
Wendy Bloembergen, Steven Bloembergen, and Nathan Jones for the presentation of a starch nanoparticle for detection of early-stage cavities
Nanoparticle-Based Targeting and Detection of Microcavities
Advanced Healthcare Materials, January 11, 2017 – Although dental caries is the most prevalent oral disease worldwide, currently, many dentists continue to use the traditional mirror and probe (dental explorer) method of caries diagnosis. This method of caries detection has the drawback that it is often difficult to distinguish between active and inactive carious lesions. In this work, novel bio-based nanoparticles are developed to specifically detect active caries in vitro. The nanoparticles are made from a cationic fluorescein-labeled food-grade starch in order to fluoresce when illuminated by a standard dental curing light, and to degrade in the oral cavity into nontoxic compounds after detecting the active carious lesion. When exposed to extracted human teeth, cationic fluorescent (+5.8 ± 1.2 mV) nanoparticles (size 101 ± 56 nm) selectively illuminate active caries, but not the healthy tooth surface. Two-photon microscopy confirms the selective binding and accumulation of cationic fluorescent nanoparticles into microscopic carious pores in enamel. These novel nanoparticles provide a unique method to assist in the early diagnosis of active carious lesions with the potential to directly impact dental treatment.
Nathan Jones Wins 2016 IADR Colgate Research in Prevention Travel Award
Nathan Jones, previously at the University of Waterloo and currently at the University of Michigan, won the 2016 IADR Colgate Research in Prevention Travel Award. The objective of this award program is to encourage young investigators to undertake research in the prevention of oral diseases and to facilitate their presentation of this work to the international dental and oral health research community.
GreenMark Biomedical Introductory Press Release
Lansing, MI – June 10, 2016 – GreenMark Biomedical Inc. today announced an agreement relating to the transfer of certain intellectual property from EcoSynthetix Inc. (TSX: ECO), a renewable chemicals company that produces a portfolio of biobased products. GreenMark, a Delaware start-up corporation with facilities in Michigan, was formed for the purpose of delivering health benefits to society through biobased targeting technologies. The company will be developing and commercializing a platform of diagnostic and therapeutic technologies using biobased, nano-scale targeting particles.
GreenMark has a collaboration network with US and Canadian universities involving health based technologies. Nathan Jones, previously at the University of Waterloo and currently at the University of Michigan, has been working with the biopolymer nanoparticles since 2009. He will be presenting some of the findings of his Ph.D. research at the International Association for Dental Research (IADR) 94th General Session & Exhibition, in Seoul, Korea.